Patent Settlements Blocking Authorized Generics May Get US Supreme Court Review
This article was originally published in SRA
Executive Summary
GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. are urging the US Supreme Court to clarify that its 2013 opinion on reverse payment settlements does not cover agreements in which the brand name drug maker promises not to launch an authorized generic1. Their prospects for getting a review are not especially strong, however, even though the topic is increasingly urgent for the pharmaceutical industry; in the three years since the original decision, only one appeals court has addressed the issue2.
You may also be interested in...
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.
Off-Label Communication: Industry Opposes Exclusion Of Phase II Data From US FDA’s Guidance
Revised draft guidance about scientific information on unapproved uses (SIUU) of medical products is “impermissibly paternalistic and overly restrictive of scientific speech,” MIWG says.